[8-K] KALA BIO, Inc. Reports Material Event

Rhea-AI Filing Summary

KALA BIO announced that it has released its quarterly results for the period ending June 30, 2025 and provided a general business and corporate update. The company has furnished a press release as Exhibit 99.1 to this Form 8-K so investors can read the full update. The filing notes that the information is being furnished (not "filed") under the Exchange Act and therefore is for disclosure rather than subject to certain filing liabilities.

Insights

Financial Analyst

Routine quarterly disclosure furnished; no financial detail in the form itself to assess performance.

The Form 8-K serves to notify the market that KALA BIO has released its Q2 results and a corporate update via a press release attached as Exhibit 99.1. Because the Form does not include financial figures or guidance, there is no new quantitative information here to change valuation models or revenue/profit expectations. Investors should review the attached press release for actual financial metrics and any management commentary that could be material.

Corporate Governance Expert

Procedural disclosure completed; filing clarifies exhibit status and includes executive signature.

The report follows standard disclosure practice by furnishing the press release and indicating the presentation is furnished, not filed, which limits certain legal exposure. The document is signed by the Chief Financial Officer and Corporate Secretary, indicating appropriate corporate authorization. This is a routine compliance filing rather than an event that, by itself, indicates governance changes or material corporate actions.

0001479419false00014794192025-08-082025-08-08

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2025

KALA BIO, Inc.

(Exact Name of Registrant as Specified in its Charter)

​

​	​	​
Delaware	001-38150	27-0604595
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

1167 Massachusetts Avenue

Arlington, MA 02476

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 996-5252

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​	​	​
Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	KALA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02.   Results of Operations and Financial Condition.

On August 8, 2025, KALA BIO, Inc. announced its financial results for the quarter ended June 30, 2025 and provided a general business and corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

​

Item 9.01.  Financial Statements and Exhibits.

(d)     Exhibits.

​	​
​	​
99.1	Press Release of KALA BIO, Inc. dated August 8, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
	KALA BIO, INC.
Date: August 8, 2025	By:	/s/ Mary Reumuth
		Mary Reumuth
		Chief Financial Officer and Corporate Secretary

​

​

​

​

FAQ

When did KALA (KALA) announce its quarterly results?

The press release is dated August 8, 2025 and reports results for the quarter ended June 30, 2025 as furnished in Exhibit 99.1.

Where can investors find the details of KALA's Q2 2025 results?

Investors should read Exhibit 99.1 attached to the Form 8-K, which contains the company's press release with the full results and corporate update.

Does this Form 8-K include KALA's financial statements or detailed metrics?

No. The Form 8-K furnishes a press release and a cover page interactive data file but does not itself include detailed financial statements or tables.

Who signed the Form 8-K for KALA?

Mary Reumuth, Chief Financial Officer and Corporate Secretary, signed the Form 8-K on behalf of the company.

Is the press release in this filing considered "filed" with the SEC?

No. The filing states the press release and related information are being furnished and are not to be deemed "filed" for certain Exchange Act liabilities.